Possibility of Neoplastic Transformation of Ovarian Endometriosis

Sergey A. Levakov; Tatyana A. Gromova

doi:10.61841/bkvbgs21

Authors

Sergey A. Levakov Doctor of Medical Sciences, Professor, Head of the Department of Gynecology and Obstetrics, I.M. Sechenov, First Moscow State Medical University (Sechenov University), Ministry of Health of Russia, 2/8 Trubetskaya Street, Moscow, Russia Author
Tatyana A. Gromova Post-graduate Student at the Department of Gynecology and Obstetrics, I.M. Sechenov, First Moscow State Medical University (Sechenov University), Ministry of Health of Russia, 2/8 Trubetskaya Street, Moscow, Russia Author

DOI:

https://doi.org/10.61841/bkvbgs21

Keywords:

Ovarian Endometriosis, Epithelial Atypia of Ovarian Endometriosis, Nuclear Hepatocytes Factor 1 Beta (HNF-1β), Clear Cell Ovarian Adenocarcinoma

Abstract

The aim of the study was to investigate the features of neoplastic endothelial transformation in the foci of ovarian endometriosis (OE).

Materials and Methods: Histologic and immunohistochemical methods were used for the study of 78 and 35 cases of OE, respectively, and 8 cases of adenocarcinomas. The authors used antibodies to Ki-67, Всl-2, р53, and nuclear hepatocytes factor 1 beta (HNF-1β).

Results: Epithelial walls of endometrial cysts had syncytial papillary changes (39.7%), metaplasia with hobnaillike cells (15.4%), atypia of epithelium with fluctuation of the expression of Ki-67 and Всl-2 from low to relatively high (41.0%), and the expression of р53 that tended to increase. The expression of HNF-1β in lesions without atypia was revealed in 56.3% of cases, and in lesions with atypia—in 94.7%, and was identified only in clear cell adenocarcinomas.

Conclusion: Hyperexpression of HNF-1β suggested adaptive character and histogenetic association of OE with clear cell ovarian tumors.

Downloads

Download data is not yet available.

References

[1] Jiang Q.Y., Wu R.J. Growth mechanisms of endometriotic cells in implanted places: A review. Gynecol

Endocrinol 2012; 28:562–67. doi: 10.3109/09513590.2011.650662. Epub 2012 Feb 2.

[2] Levakov S.A., Gromova T.A., Kedrova A.G., Sheshukova N.A. Endometriosis-associated ovarian cancer.

2016, №4, v. 12, 47-51.

[3] Pearce C.L., Templeman C., Rossing M.A., Lee A., Near A.M., Webb P.M., et al. Association between

Endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.

LANCET Oncol 2012:13-385. doi: 10.1016/S1470-2045(11)70404-1. Epub 2012 Feb 22.

[4] Krawczyk N., Banys-Paluchowski M., Schmidt D., Ulrich U., Fehm T. Endometriosis-associated

Malignancy. Geburtshilfe Frauenheilkd. 2016 Feb; 76(2): 176–181. doi: 10.1055/s-0035-1558239.

[5] Yu H.C., Lin C.Y., Chang W.C., Shen B.J., Chang W.P., Chuang C.M., et al. Increased association

between endometriosis and endometrial cancer: a nationwide population-based retrospective cohort study.

Int J Gynecol Cancer. 2015 Mar;25(3):447-52. doi: 10.1097/IGC.0000000000000384.

[6] Amano Y., Mandai M., Yamaguchi K., Matsumura N., Kharma B., Baba T., et al. Metabolic alterations

caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival. Oncotarget.

2015;22;6(28):26002-17. doi: 10.18632/oncotarget.4692.

[7] Mandai M., Amano Y., Yamaguchi K., Matsumura N., Baba T., Konishi I. Ovarian clear cell carcinoma

meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction.

Oncotarget. 2015;13;6(31):30704-14. doi: 10.18632/oncotarget.5228.

[8] Suzuki E., Kajita S., Takahashi H., Matsumoto T., Tsuruta T., Saegusa M. Transcriptional upregulation of

HNF-1β by NF-κB in ovarian clear cell carcinoma modulates susceptibility to apoptosis through alteration

in bcl-2 expression. Lab Invest. 2015;95(8):962-72. doi: 10.1038/labinvest.2015.73. Epub 2015 Jun 1.

[9] DeLair D., Han G., Irving J.A., Leung S., Ewanowich C.A., Longacre T.A., et al. HNF-1β in ovarian

carcinomas with serous and clear cell change. Int J Gynecol Pathol. 2013;32(6):541-6. doi:

10.1097/PGP.0b013e318273fd07.

[10] Hoang L.N., Han G., McConechy M., Lau S., Chow C., Gilks C.B., et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma-diagnostic utility of HNF-1β and estrogen receptor. Histopathology. 2014;64(4):585-96. doi: 10.1111/his.12286. Epub 2013 Dec 7.

[11] Kao Y.C., Lin M.C., Lin W.C., Jeng Y.M., Mao T.L. Utility of hepatocyte nuclear factor-1β as a

diagnostic marker in ovarian carcinomas with clear cells. Histopathology. 2012;61(5):760-8. doi:

10.1111/j.1365-2559.2012.04267.x. Epub 2012 Jul 2.

[12] Kurman R.J., Ellenson H., Ronnett L., Brigitte M. (Eds.). Blaustein’s Pathology of the Female Genital

Tract. 6th Ed., 2011.

[13] Kurman RJ, Carcanglu ML, Herrington CS, Young RH, eds. WHO Classification of Tumours of female

Reproductive Organs. 4th ed. Lyon: WHO Press; 2014.

[14] Zaino, R., Carinelli, S.G., Ellenson, L.H. Tumors of the uterine corpus: epithelial tumors and precursors.

WHO Press, Lyon; 2014: 125–126.

[15] Brinkmann V., Abu Abed U., Goosmann C., Zychlinsky A. Immunodetection of NETs in Paraffin-Embedded Tissue. Front Immunol. 2016 Nov 22;7:513. eCollection 2016.

[16] Mojiri A., Stoletov K., Carrillo M.A., Willetts L., Jain S., Godbout R. et al. Functional assessment of von

von Willebrand factor expression by cancer cells of non-endothelial origin. Oncotarget. 2017 Feb

21;8(8):13015-13029. doi: 10.18632/oncotarget.14273.

[17] Cohen D.A., Dabbs D.J., Cooper K.L., Amin M., Jones T.E., Jones M.W. et al. Interobserver Agreement

Among Pathologists for Semiquantitative Hormone Receptor Scoring in Breast Carcinoma. Am J Clin

Pathol. (2012) 138 (6): 796-802. doi: 10.1309/AJCP6DKRND5CKVDD.

[18] Clinical recommendations. Endometriosis: diagnostics, treatment, and rehabilitation. – M., 2013, p. 1-15.

[19] Zajrat'janc O.V., Adamjan L.V., Andreeva E.N. et al. Molecular-biological peculiarities of ectopic endometrium in patients with genital endometriosis. Archives of Pathology. 2010. №5. p.6-12.